Current and emerging treatment options i
โ
Elias Jabbour; Jorge E. Cortes; Francis J. Giles; Susan O'Brien; Hagop M. Kantar
๐
Article
๐
2007
๐
John Wiley and Sons
๐
English
โ 210 KB
## Abstract Treatments for chronic myeloid leukemia (CML) represent a success story in molecular medicine. The development of imatinib, a tyrosine kinase inhibitor (TKI) targeted against the causative BcrโAbl oncoprotein in CML, has resulted in hematologic and cytogenetic remissions in all phases o